Milrinon Tillomed (Milrinone)

Milrinone blocks the enzyme phosphodiesterase‑3, leading to increased intracellular cyclic AMP. Higher cAMP levels enhance calcium entry into cardiac cells, boosting contractility, while also causing relaxation of vascular smooth muscle, which reduces systemic vascular resistance and improves cardiac output.

The dosing regimen for Milrinon Tillomed is determined by the prescribing clinician based on the patient’s clinical status, weight, renal function, and response to therapy. The prescriber sets the infusion rate and duration according to established guidelines.

Safety data for milrinone in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

To request Milrinon Tillomed, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Milrinone differs from catecholamine inotropes such as dobutamine by acting via phosphodiesterase‑3 inhibition rather than beta‑adrenergic stimulation. This mechanism provides both inotropic support and vasodilation, which can be advantageous in patients with high systemic vascular resistance, but it may also increase the risk of hypotension.

Milrinon Tillomed should be stored at 2‑8 °C, protected from light, and must not be frozen. The solution should be kept in its original packaging until use and handled with aseptic technique to maintain sterility.

Milrinon Tillomed is administered intravenously, typically as a continuous infusion after an initial loading dose. Administration occurs in a monitored setting such as an intensive‑care unit, with continuous observation of blood pressure, heart rate, and cardiac rhythm.

The most serious risks include severe hypotension, life‑threatening ventricular arrhythmias, myocardial ischemia, and rare allergic reactions. Patients should be closely monitored for these events, and therapy should be stopped immediately if they occur.

Milrinon Tillomed is contraindicated in patients with severe aortic stenosis, uncontrolled ventricular arrhythmias, or known hypersensitivity to milrinone or any formulation component. Caution is also advised in recent myocardial infarction and severe renal impairment.